Categories: Healthcare

Bladder Cancer Drugs Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends|Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Celgene Corporation, AstraZeneca PLC

The bladder cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $7.28 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to ongoing research and development, emerging markets, healthcare infrastructure development, strategic alliances and collaborations. Major trends in the forecast period include precision medicine, immunotherapy and targeted therapies, personalized medicine, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring, patient-centric care.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Segmentation & Regional Insights
The bladder cancer drugs market covered in this report is segmented –

1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer
2) By Application: Low-Grade Tumors, High-Grade Tumors
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

North America was the largest region in the bladder cancer drugs market in 2023. The Middle East is expected to be the fastest-growing region in the bladder cancer drugs market during the forecast period. The regions covered in the bladder cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2586&type=smp

Major Driver Impacting Market Growth
The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, an increase in smoking habits, and consuming water that contains Arsenic increase the chances of blood cancer. According to the American Cancer Society, there were an estimated 82,290 new cases of bladder cancer in the United States in 2023, with about 62,420 cases in men and 19,870 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the bladder cancer drugs market.

Key Industry Players
Major companies operating in the bladder cancer drugs market include Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), AstraZeneca PLC, GlaxoSmithKline plc, Sanofi S.A., F. Hoffmann-La Roche Ltd., Novartis International AG, Johnson & Johnson, Merck & Co. Inc., Vault Pharma Inc., Vyriad Inc., Boehringer Ingelheim International GmbH, Bayer AG, Asieris Pharmaceuticals Co. Ltd., Asana BioSciences LLC, Array BioPharma Inc., Archivel Farma S.L., AndroScience Corporation, Amgen Inc., Altor Bioscience Corporation, Alligator Bioscience AB, Adaptimmune Therapeutics plc, UroGen Pharma Ltd., Seagen Inc., Incyte Corporation, Mayo Foundation for Medical Education and Research, AbbVie Inc., Eisai Co. Ltd., Ipsen S.A., Janssen Pharmaceutica NV, Kyowa Kirin Co. Ltd., Menarini Group, Ono Pharmaceutical Co. Ltd., Pierre Fabre S.A., Taiho Pharmaceutical Co. Ltd.

The bladder cancer drugs market report table of contents includes: